 | Up a level |
De Jong, W.H. and Borges, T. and Ion, R.M. and Panagiotakos , D. and Testai, E. and Vermeire, T. and Scott, M. and Samaras, T. and Proykova, A. and Kraetke, R. and Hoet, P. and Bertollini, R. and Duarte-Davidson, R. and Slama, R. and de Voogt, P. and Kraetke, R. and Proykova, A. and Vighi, M. (2020) Guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devices covering phthalates which are carcinogenic, mutagenic, toxic to reproduction (CMR) or have endocrine-disrupting (ED) properties. Regulatory Toxicology and pharmacology, 111. p. 104546.
Bertollini, R. and Borges, T. and De Jong, W. and de Voogt, P. and Duarte-Davidson, R. and Hoet, P. and Ion, R.M. and Krätke, R. and Panagiotakos , D. and Proykova, A. and Samaras, T. and Scott, M. and Testai, E. and Vermeire, T. and Vighi, M. and Zacharov, S. (2022) SCHEER (Scientific Committee on Health, Environmental and Emerging Risks). SCHEER Statement II on Emerging Issues (2022), 13 January 2022. Other. European Commission.
Proykova, A. and Kraetke, R. and Bertollini, R. and Borges, T. and Duarte-Davidson, R. and Panagiotakos , D. and Slama, R. and Scott, M. and Testai, E. and Vermeire, T. and Vighi, M. (2018) Memorandum on weight of evidence and uncertainties Revision 2018. Technical Report. European Commission, Luxembourg.
